Greg Hu

Just a guy passionate about a few stocks. Not a scientist, or an investment guru. Please do your own research related to any stocks I mention.

[Greg Hu @WizardWallSt]

@RazorSharpDNA This company has incredible value as long as the trials continue to be successful. My bet is...

Value > Dilution = 📈 !

Thanks for your post.

[Greg Hu @WizardWallSt]

@Irisa_Yue Some trading, but mostly holding. Also hoping, lots of hoping.

[Greg Hu @WizardWallSt]

$CRBU Last year around this time CRBU bounced from sub $2 in September up to the $2.80s in October. Let's hope history repeats itself and then CRBU keeps the momentum going.

[Greg Hu @WizardWallSt]

@dadbodfamilyguy That would certainly create an impressive pipeline.

[Greg Hu @WizardWallSt]

@dadbodfamilyguy They certainly appear to be gearing up! Thank you for your post.

[Greg Hu @WizardWallSt]

$CRBU A great day for the herd and for most other biotechs. I believe that just like how AI stocks have been the market movers in the past few years, gene editing stocks will market mammoths in the future...and they are currently so cheap! Do your research! Not financial advice!

[Greg Hu @WizardWallSt]

$CRBU $ALLO $CRSP I am convinced these three companies represent the future of medicine. If clinical trials continue to show promise sky's the limit for healthcare and the stock price.

[Greg Hu @WizardWallSt]

$CRBU Sweet after hours bounce! Could be a bottom. Let's get this thing back into the $2s and beyond!

[Greg Hu @WizardWallSt]

$CRBU It seems one of these talks is very much related to commercialization.

[Caribou Biosciences @CaribouBio]

In Boston next week? Check out the presentations from our very own Enrique Zudaire and Justin Skoble at the 11th Annual CAR-TCR Summit.

Learn more: https://t.co/HyUs8cnRaD #CRISPR #CellTherapy $CRBU

[Greg Hu @WizardWallSt]

I really like your use of "off the shelf gold mine". That is a great way to put it. We all need to keep an eye on the prize here.

[Eleftheria @eldermember]

@ahenryokc @WizardWallSt @dadbodfamilyguy @SetlistCapital @Theoriatheoria I think the more plausible explanation is that the market is pricing in the risk of dilution and bad data, coupled with a choppy September market and a long gap until the next catalyst, making it a short target. If durability holds, the platform is an off the shelf gold mine.

[Greg Hu @WizardWallSt]

$CRBU When phase 3 starts whether with a partnership or dilution, we are in a whole different league. If the data remains good, we are not going to have to worry about anything.

[Greg Hu @WizardWallSt]

$CRBU A rough few weeks. Just going to have to wait it out for better days. A month or two to grin and bear it. The science and market are there, we will see this turn one day. We are just experiencing the swings this stock does during this stage of its existence. Not unexpected

[Greg Hu @WizardWallSt]

@DustinHuntwn $CRBU Develops allogeneic, or off-the-shelf, CAR-T cell therapies. This is a really big deal in biotech. Check out their analyst ratings and do your own research.

[Greg Hu @WizardWallSt]

@SetlistCapital @dadbodfamilyguy @Theoriatheoria It's this god-damned new wand. 😂

[Greg Hu @WizardWallSt]

$CRBU The fact that the largest asset manager in the world, Blackrock, had 1,843,794 shares in July 2025 and increased their share to 5,332,610 shares by July 2026 has got to say something about this stock. They now own over 7% of the company.

[Greg Hu @WizardWallSt]

@ahenryokc @dadbodfamilyguy @SetlistCapital @Theoriatheoria I don't think it's lights out! That's a Julia thing, not a you thing. It's only lights out if Phase 3 goes horribly wrong which I don't expect. Even dilution doesn't really bother me. I just want to get phase 3 started.

[Greg Hu @WizardWallSt]

@ahenryokc @dadbodfamilyguy @SetlistCapital @Theoriatheoria Excellent research. Hopefully they hire the right person next go-round.

[Greg Hu @WizardWallSt]

@dadbodfamilyguy @SetlistCapital @ahenryokc @Theoriatheoria I am with you. This should be viewed as a positive. There are some unwarranted fatalistic posts out there. Sadly, there has also been some downward momentum as of late, but it seems to be based on trading nonsense, not the actual company's performance. This stock will rise again

[Greg Hu @WizardWallSt]

@SetlistCapital @dadbodfamilyguy @Theoriatheoria Says who?

Would not be bad if they bring some rockstar in, but I don't see the news anywhere.

[Greg Hu @WizardWallSt]

@AIHealthUncut @AIHealthUncut
I hope your panel talks about Caribou Biosciences because they are a woman founded (Noble Prize Winner Jennifer Doudna) and run (CEO Rachel Haurwitz) biotech company making more accessible cancer therapies. $CRBU has stellar upside potential and analyst coverage.